CLRB (Cellectar Biosciences) Debt-to-Equity : 0.04 (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Cellectar Biosciences Debt-to-Equity?

Cellectar Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.08 Mil. Cellectar Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.41 Mil. Cellectar Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $14.30 Mil. Cellectar Biosciences's debt to equity for the quarter that ended in Dec. 2024 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cellectar Biosciences's Debt-to-Equity or its related term are showing as below:

CLRB' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.04 Med: 0.02 Max: 0.21
Current: 0.04

During the past 13 years, the highest Debt-to-Equity Ratio of Cellectar Biosciences was 0.21. The lowest was -0.04. And the median was 0.02.

CLRB's Debt-to-Equity is ranked better than
75.44% of 1014 companies
in the Biotechnology industry
Industry Median: 0.14 vs CLRB: 0.04

Cellectar Biosciences Debt-to-Equity Historical Data

The historical data trend for Cellectar Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Debt-to-Equity Chart

Cellectar Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.07

-0.04

0.04

Cellectar Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															-0.04	0.02	0.04	0.03	0.04

Competitive Comparison of Cellectar Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Cellectar Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectar Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Cellectar Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cellectar Biosciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.084	+	0.41)	/	14.295
	=	0.03

Cellectar Biosciences's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.084	+	0.41)	/	14.295
	=	0.03

Cellectar Biosciences (NAS:CLRB) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cellectar Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

NV4:Germany NV4:Germany

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.

Executives

Jarrod Longcor	officer: Chief Business Officer	C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Andrei Shustov	officer: Senior Vice President, Medical	7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea	officer: Chief Commercial Officer	7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean	officer: Chief Financial Officer	C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll	director
Asher Chanan-khan	director	C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso	director, officer: President and CEO	C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Friend John E. Ii	officer: VP, Chief Medical Officer	26 ORCHARD LANE, COLT NECK NJ 07722
John Neis	director	505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren	director	3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev	officer: Chief Medical Officer	15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355